EMPA-REG OUTCOME: 3 years on, what are the implications for clinical practice?

Excess mortality in type 2 diabetes is largely related to an increased incidence of cardiovascular disease.1 Traditionally, the management of type 2 diabetes has focused on glycaemic control, but, with cardiovascular outcomes trials now providing evidence of a cardiovascular benefit with some glucose-lowering agents, is it time to re-think the way we manage type 2 diabetes?

3-years on from EMPA-REG OUTCOME, the cardiovascular outcomes trial for empagliflozin▼,2 guidelines around the world are being updated, placing greater emphasis on the management of cardiovascular risk in the treatment of type 2 diabetes, but how can these results best be incorporated into our own clinical practice?

Join Dr Kevin Fernando and Dr Yassir Javaid as they reflect on the results from cardiovascular outcomes trials and consider what these mean for our clinical practice.

References

  1. Tancredi M et al. N Engl J Med. 2015;373:1720–1732.
  2. Zinman B et al. N Engl J Med. 2015;373:2117–2128.

Learning Outcomes

By the end of this session, delegates will:

  • have received an overview of the results from EMPA-REG OUTCOME and other cardiovascular outcomes trials in type 2 diabetes
  • understand the impact that the results from cardiovascular outcomes trials have had on international guidance recommendations
  • be able to reflect on the importance of managing cardiovascular risk in patients with type 2 diabetes.

This promotional session is sponsored by the Boehringer Ingelheim and Lilly Diabetes Alliance. The funding provided for this session includes speaker honoraria and presentation development support. The presentation has been reviewed for medical accuracy and compliance with applicable laws and regulations.

Jardiance (empagliflozin) therapeutic indication

Jardiance is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise

  • as monotherapy when metformin is considered inappropriate due to intolerance
  • in addition to other medicinal products for the treatment of diabetes

For study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1 [of the Summary of Product Characteristics].

Please click here for prescribing information

PC-UK-100156 | November 2018

This promotional session is sponsored by the Boehringer Ingelheim and Lilly Diabetes Alliance. The funding provided for this session includes speaker honoraria and presentation development support. The presentation has been reviewed for medical accuracy and compliance with applicable laws and regulations.

Thursday 15th November 2018

15:55 - 16:25

Diabetes Co-Morbidities: Cardiovascular & Retinopathy

Cardiology Icon

Speakers

GP Partner & Medical Education & Scottish Lead, North Berwick Health Centre, GPwSI Diabetes, Primary Care Diabetes Society
Dr Yassir Javaid
GPwSI Cardiology & Cardiovascular Lead, Nene CCG

Our site is intended for UK Healthcare Professionals

Are you a UK Healthcare Professional?

We’re sending you to our partner charity’s site. 

DRWF provide information and support for people with diabetes and their friends & families